Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 370

1.

Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors.

Zhu X, Holmsen E, Park S, Willingham MC, Qi J, Cheng SY.

Oncotarget. 2018 Oct 23;9(83):35408-35421. doi: 10.18632/oncotarget.26253. eCollection 2018 Oct 23.

2.

Metformin and JQ1 synergistically inhibit obesity-activated thyroid cancer.

Park S, Willingham MC, Qi J, Cheng SY.

Endocr Relat Cancer. 2018 Oct;25(10):865-877. doi: 10.1530/ERC-18-0071. Epub 2018 Jun 18.

PMID:
29914872
3.

Inhibition of STAT3 signaling blocks obesity-induced mammary hyperplasia in a mouse model.

Park JW, Zhao L, Willingham MC, Cheng SY.

Am J Cancer Res. 2017 Mar 1;7(3):727-739. eCollection 2017.

4.

Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.

Enomoto K, Zhu X, Park S, Zhao L, Zhu YJ, Willingham MC, Qi J, Copland JA, Meltzer P, Cheng SY.

J Clin Endocrinol Metab. 2017 Jul 1;102(7):2268-2280. doi: 10.1210/jc.2016-3771.

5.

Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model.

Zhu X, Enomoto K, Zhao L, Zhu YJ, Willingham MC, Meltzer P, Qi J, Cheng SY.

Clin Cancer Res. 2017 Jan 15;23(2):430-440. doi: 10.1158/1078-0432.CCR-16-0914. Epub 2016 Jul 20.

6.

SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model.

Zhu X, Kim DW, Zhao L, Willingham MC, Cheng SY.

Endocr Relat Cancer. 2016 Jul;23(7):521-33. doi: 10.1530/ERC-16-0103. Epub 2016 Jun 7.

7.

Loss of tyrosine phosphorylation at Y406 abrogates the tumor suppressor functions of the thyroid hormone receptor β.

Park JW, Zhao L, Willingham MC, Cheng SY.

Mol Carcinog. 2017 Feb;56(2):489-498. doi: 10.1002/mc.22511. Epub 2016 Jun 14.

PMID:
27254276
8.

Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model.

Park JW, Han CR, Zhao L, Willingham MC, Cheng SY.

Endocr Relat Cancer. 2016 Jan;23(1):53-63. doi: 10.1530/ERC-15-0417. Epub 2015 Nov 9.

9.

F10 Inhibits Growth of PC3 Xenografts and Enhances the Effects of Radiation Therapy.

Gmeiner WH, Willingham MC, Bourland JD, Hatcher HC, Smith TL, D'Agostino RB Jr, Blackstock W.

J Clin Oncol Res. 2014 Jul-Aug;2(4). pii: 1028.

10.

Testosterone regulates thyroid cancer progression by modifying tumor suppressor genes and tumor immunity.

Zhang LJ, Xiong Y, Nilubol N, He M, Bommareddi S, Zhu X, Jia L, Xiao Z, Park JW, Xu X, Patel D, Willingham MC, Cheng SY, Kebebew E.

Carcinogenesis. 2015 Apr;36(4):420-8. doi: 10.1093/carcin/bgv001. Epub 2015 Jan 9.

11.

DMP1β, a splice isoform of the tumour suppressor DMP1 locus, induces proliferation and progression of breast cancer.

Maglic D, Stovall DB, Cline JM, Fry EA, Mallakin A, Taneja P, Caudell DL, Willingham MC, Sui G, Inoue K.

J Pathol. 2015 May;236(1):90-102. doi: 10.1002/path.4504. Epub 2015 Feb 9.

12.

Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.

Zhu X, Zhao L, Park JW, Willingham MC, Cheng SY.

Neoplasia. 2014 Sep;16(9):757-69. doi: 10.1016/j.neo.2014.08.003.

13.

A histone deacetylase inhibitor improves hypothyroidism caused by a TRα1 mutant.

Kim DW, Park JW, Willingham MC, Cheng SY.

Hum Mol Genet. 2014 May 15;23(10):2651-64. doi: 10.1093/hmg/ddt660. Epub 2013 Dec 30.

14.

Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer.

Fozzatti L, Park JW, Zhao L, Willingham MC, Cheng SY.

PLoS One. 2013 Jun 26;8(6):e67954. doi: 10.1371/journal.pone.0067954. Print 2013.

15.

Diet-induced obesity increases tumor growth and promotes anaplastic change in thyroid cancer in a mouse model.

Kim WG, Park JW, Willingham MC, Cheng SY.

Endocrinology. 2013 Aug;154(8):2936-47. doi: 10.1210/en.2013-1128. Epub 2013 Jun 7.

16.

Inhibition of tumorigenesis by the thyroid hormone receptor β in xenograft models.

Kim WG, Zhao L, Kim DW, Willingham MC, Cheng SY.

Thyroid. 2014 Feb;24(2):260-9. doi: 10.1089/thy.2013.0054. Epub 2013 Sep 4.

17.

Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis.

Nagalla S, Chou JW, Willingham MC, Ruiz J, Vaughn JP, Dubey P, Lash TL, Hamilton-Dutoit SJ, Bergh J, Sotiriou C, Black MA, Miller LD.

Genome Biol. 2013 Apr 29;14(4):R34. doi: 10.1186/gb-2013-14-4-r34.

18.

Nuclear receptor corepressor (NCOR1) regulates in vivo actions of a mutated thyroid hormone receptor α.

Fozzatti L, Kim DW, Park JW, Willingham MC, Hollenberg AN, Cheng SY.

Proc Natl Acad Sci U S A. 2013 May 7;110(19):7850-5. doi: 10.1073/pnas.1222334110. Epub 2013 Apr 22.

19.

Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer.

Maglic D, Zhu S, Fry EA, Taneja P, Kai F, Kendig RD, Sugiyama T, Miller LD, Willingham MC, Inoue K.

Oncogene. 2013 Aug 29;32(35):4120-9. doi: 10.1038/onc.2012.423. Epub 2012 Oct 8.

20.

Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis.

Krishnan B, Smith TL, Dubey P, Zapadka ME, Torti FM, Willingham MC, Tallant EA, Gallagher PE.

Prostate. 2013 Jan;73(1):71-82. doi: 10.1002/pros.22542. Epub 2012 May 29.

21.

SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer.

Kim WG, Guigon CJ, Fozzatti L, Park JW, Lu C, Willingham MC, Cheng SY.

Clin Cancer Res. 2012 Mar 1;18(5):1281-90. doi: 10.1158/1078-0432.CCR-11-2892. Epub 2012 Jan 23.

22.

Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1).

Fozzatti L, Lu C, Kim DW, Park JW, Astapova I, Gavrilova O, Willingham MC, Hollenberg AN, Cheng SY.

Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17462-7. doi: 10.1073/pnas.1107474108. Epub 2011 Oct 10.

23.

Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma.

Lu C, Zhu X, Willingham MC, Cheng SY.

Oncogene. 2012 Apr 19;31(16):2007-16. doi: 10.1038/onc.2011.390. Epub 2011 Sep 12.

24.

Novel innate cancer killing activity in humans.

Blanks MJ, Stehle JR Jr, Du W, Adams JM, Willingham MC, Allen GO, Hu JJ, Lovato J, Molnar I, Cui Z.

Cancer Cell Int. 2011 Aug 3;11:26. doi: 10.1186/1475-2867-11-26.

25.

Endogenous synthesis of n-3 polyunsaturated fatty acids in Fat-1 mice is associated with increased mammary gland and liver syndecan-1.

Sun H, Hu Y, Gu Z, Wilson MD, Chen YQ, Rudel LL, Willingham MC, Edwards IJ.

PLoS One. 2011;6(5):e20502. doi: 10.1371/journal.pone.0020502. Epub 2011 May 31.

26.
27.

Mutation of thyroid hormone receptor-β in mice predisposes to the development of mammary tumors.

Guigon CJ, Kim DW, Willingham MC, Cheng SY.

Oncogene. 2011 Jul 28;30(30):3381-90. doi: 10.1038/onc.2011.50. Epub 2011 Mar 14.

28.

Loss of heterozygosity and SOSTDC1 in adult and pediatric renal tumors.

Blish KR, Clausen KA, Hawkins GA, Garvin AJ, Willingham MC, Turner JC, Torti FM, Torti SV.

J Exp Clin Cancer Res. 2010 Nov 16;29:147. doi: 10.1186/1756-9966-29-147.

29.

Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development.

Taneja P, Maglic D, Kai F, Sugiyama T, Kendig RD, Frazier DP, Willingham MC, Inoue K.

Cancer Res. 2010 Nov 15;70(22):9084-94. doi: 10.1158/0008-5472.CAN-10-0159. Epub 2010 Nov 9.

30.

Ferroportin and iron regulation in breast cancer progression and prognosis.

Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, Torti FM.

Sci Transl Med. 2010 Aug 4;2(43):43ra56. doi: 10.1126/scisignal.3001127. Erratum in: Sci Transl Med. 2010 Aug 25;2(46):46er1.

31.

The spectrum of resistance in SR/CR mice: the critical role of chemoattraction in the cancer/leukocyte interaction.

Riedlinger G, Adams J, Stehle JR Jr, Blanks MJ, Sanders AM, Hicks AM, Willingham MC, Cui Z.

BMC Cancer. 2010 May 3;10:179. doi: 10.1186/1471-2407-10-179.

32.

In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.

Akins EJ, Moore ML, Tang S, Willingham MC, Tooze JA, Dubey P.

Cancer Res. 2010 May 1;70(9):3473-82. doi: 10.1158/0008-5472.CAN-09-2490. Epub 2010 Apr 20.

33.

Cancer resistance of SR/CR mice in the genetic knockout backgrounds of leukocyte effector mechanisms: determinations for functional requirements.

Sanders AM, Stehle JR Jr, Blanks MJ, Riedlinger G, Kim-Shapiro JW, Monjazeb AM, Adams JM, Willingham MC, Cui Z.

BMC Cancer. 2010 Mar 31;10:121. doi: 10.1186/1471-2407-10-121.

34.

Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer.

Guigon CJ, Fozzatti L, Lu C, Willingham MC, Cheng SY.

Carcinogenesis. 2010 Jul;31(7):1284-91. doi: 10.1093/carcin/bgq059. Epub 2010 Mar 18.

35.

Inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) prevents dietary cholesterol-associated steatosis by enhancing hepatic triglyceride mobilization.

Alger HM, Brown JM, Sawyer JK, Kelley KL, Shah R, Wilson MD, Willingham MC, Rudel LL.

J Biol Chem. 2010 May 7;285(19):14267-74. doi: 10.1074/jbc.M110.118422. Epub 2010 Mar 15.

36.

Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma.

Lu C, Zhao L, Ying H, Willingham MC, Cheng SY.

Endocrinology. 2010 Apr;151(4):1929-39. doi: 10.1210/en.2009-1017. Epub 2010 Feb 4.

37.

Thyroid hormone receptors are tumor suppressors in a mouse model of metastatic follicular thyroid carcinoma.

Zhu XG, Zhao L, Willingham MC, Cheng SY.

Oncogene. 2010 Apr 1;29(13):1909-19. doi: 10.1038/onc.2009.476. Epub 2010 Jan 11.

38.

Fluorescence labeling of intracellular antigens of attached or suspended tissue-culture cells.

Willingham MC.

Methods Mol Biol. 2010;588:153-64. doi: 10.1007/978-1-59745-324-0_18.

PMID:
20012829
39.

Fluorescence labeling of surface antigens of attached or suspended tissue-culture cells.

Willingham MC.

Methods Mol Biol. 2010;588:143-51. doi: 10.1007/978-1-59745-324-0_17.

PMID:
20012828
40.

The Arf-inducing transcription factor Dmp1 encodes a transcriptional activator of amphiregulin, thrombospondin-1, JunB and Egr1.

Mallakin A, Sugiyama T, Kai F, Taneja P, Kendig RD, Frazier DP, Maglic D, Matise LA, Willingham MC, Inoue K.

Int J Cancer. 2010 Mar 15;126(6):1403-16. doi: 10.1002/ijc.24938.

41.

Impact of sex, MHC, and age of recipients on the therapeutic effect of transferred leukocytes from cancer-resistant SR/CR mice.

Stehle JR Jr, Blanks MJ, Riedlinger G, Kim-Shapiro JW, Sanders AM, Adams JM, Willingham MC, Cui Z.

BMC Cancer. 2009 Sep 15;9:328. doi: 10.1186/1471-2407-9-328.

42.

Distinct dysregulation of lipid metabolism by unliganded thyroid hormone receptor isoforms.

Araki O, Ying H, Zhu XG, Willingham MC, Cheng SY.

Mol Endocrinol. 2009 Mar;23(3):308-15. doi: 10.1210/me.2008-0311. Epub 2009 Jan 8.

43.

PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.

Guigon CJ, Zhao L, Willingham MC, Cheng SY.

Oncogene. 2009 Jan 29;28(4):509-17. doi: 10.1038/onc.2008.407. Epub 2008 Nov 10.

44.

Topology of NGEP, a prostate-specific cell:cell junction protein widely expressed in many cancers of different grade level.

Das S, Hahn Y, Walker DA, Nagata S, Willingham MC, Peehl DM, Bera TK, Lee B, Pastan I.

Cancer Res. 2008 Aug 1;68(15):6306-12. doi: 10.1158/0008-5472.CAN-08-0870.

45.

In situ immunocytochemical detection of altered membrane composition induced by cell-cell contact in cultured mammalian cells.

Du W, Cui Z, Tsui ZC, Chen Q, Willingham MC.

Microsc Res Tech. 2008 Oct;71(10):749-59. doi: 10.1002/jemt.20616.

PMID:
18618594
46.

Role of DMP1 and its future in lung cancer diagnostics.

Sugiyama T, Frazier DP, Taneja P, Morgan RL, Willingham MC, Inoue K.

Expert Rev Mol Diagn. 2008 Jul;8(4):435-47. doi: 10.1586/14737159.8.4.435. Review. Erratum in: Expert Rev Mol Diagn. 2008 Sep;8(5):670.

47.

Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages.

Zhu X, Lee JY, Timmins JM, Brown JM, Boudyguina E, Mulya A, Gebre AK, Willingham MC, Hiltbold EM, Mishra N, Maeda N, Parks JS.

J Biol Chem. 2008 Aug 22;283(34):22930-41. doi: 10.1074/jbc.M801408200. Epub 2008 Jun 14.

48.

Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor.

Guigon CJ, Zhao L, Lu C, Willingham MC, Cheng SY.

Mol Cell Biol. 2008 Jul;28(14):4598-608. doi: 10.1128/MCB.02192-07. Epub 2008 May 12.

49.

Novel translocation responses of cytosolic phospholipase A2alpha fluorescent proteins.

Wooten RE, Willingham MC, Daniel LW, Leslie CC, Rogers LC, Sergeant S, O'Flaherty JT.

Biochim Biophys Acta. 2008 Aug;1783(8):1544-50. doi: 10.1016/j.bbamcr.2008.03.008. Epub 2008 Mar 21.

50.

Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors.

Lu C, Willingham MC, Furuya F, Cheng SY.

Endocrinology. 2008 Jul;149(7):3339-45. doi: 10.1210/en.2007-1696. Epub 2008 Mar 20.

Supplemental Content

Loading ...
Support Center